ME/CFS: efficacy of repeat immunoadsorption

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: efficacy of repeat Immunoadsorption, by  Markus Tölle, Helma Freitag, Michaela Antelmann, Jelka Hartwig, Mirjam Schuchardt, Markus van der Giet, Kai-Uwe Eckardt, Patricia Grabowski, and Carmen Scheibenbogen in J. Clin. Med. 2020, 9(8), 2443; [doi.org/10.3390/jcm9082443] Published: 30 July 2020

 

Research abstract:

(1) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex neuroimmunological disease.

There is evidence for an autoimmune mechanism for ME/CFS with an infection-triggered onset and dysfunction of ß2-adrenoreceptor antibodies (ß2AR-AB). In a first proof-of-concept study, we could show that IA was effective to reduce ß2AR-AB and led to improvement of various symptoms. (2)

Five of the ME/CFS patients who had clinical improvement following treatment with a five-day IA were retreated in the current study about two years later with a modified IA protocol. The severity of symptoms was assessed by disease specific scores during a follow-up period of 12 months. The antibodies were determined by ELISA. (3)

The modified IA treatment protocol resulted in a remarkable similar clinical response. The treatment was well tolerated and 80–90% decline of total IgG and ß2AR-AB was achieved. Four patients showed a rapid improvement in several clinical symptoms during IA therapy, lasting for six to 12 months. One patient had no improvement. (4)

We could provide further evidence that IA has clinical efficacy in patients with ME/CFS. Data from our pilot trial warrant further controlled studies in ME/CFS.

Posted in News | Tagged , , , , , , , , , , , | Comments Off on ME/CFS: efficacy of repeat immunoadsorption

Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS

Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS, by  in Work 2020 [DOI: 10.3233/WOR-203177]

 

Research abstract:

BACKGROUND:

The search for a biomarker specific for ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) has been long, arduous and, to date, unsuccessful. Researchers need to consider their expenditures on each new candidate biomarker. In a previous study of antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer lymphocytes, we found lower ADCC for ME/CFS patients vs. unrelated donors but ruled against low ADCC as a biomarker because of similar ADCC for patients vs. their family members without ME/CFS.

OBJECTIVE:

We applied inclusion of family members without ME/CFS, from families with multiple CFS patients, as a second non-ME/CFS control group in order to re-examine inflammation in ME/CFS.

METHOD:

Total and CD16A-positive ‘non-classical’ anti-inflammatory monocytes were monitored.

RESULTS:

Non-classical monocytes were elevated for patients vs. unrelated healthy donors but these differences were insignificant between patients vs. unaffected family members.

CONCLUSIONS:

Inclusion of family members ruled against biomarker considerations for the monocytes characterized. These pilot findings for the non-classical monocytes are novel in the field of ME/CFS. We recommend that occupational therapists advocate and explain to family members without ME/CFS the need for the family members’ participation as a second set of controls in pilot studies to rapidly eliminate false biomarkers, optimize patient antibody-dependent cell-mediated cytotoxicity participation, and save researchers’ labor.

Posted in News | Tagged , , , , , , , , , , | Comments Off on Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS

Impact of ME on treatment of comorbidities: a lived experience

Impact of myalgic encephalomyelitis on treatment of  comorbidities: a lived experience, by Denise Lopez-Majano in Work vol. 66, no. 2, pp. 309-313, 20 Jul 2020 [DOI: 10.3233/WOR-203175]

 

Abstract:

Myalgic Encephalomyelitis (ME) is a complex, chronic, disabling, multi-system disease with no FDA-approved treatments.

ME greatly impacts quality of life (QoL) with studies showing that people with ME often have worse quality of life than people with sickle cell anemia and cystic fibrosis, among other chronic diseases.

People with ME frequently have comorbidities, which, if treated, could improve quality of life. However, the pervasive impact of ME makes treatment of comorbidities difficult. When trying to treat comorbidities it is therefore important for rehabilitation specialists to understand the impact of ME on day-to-day life in order to avoid treatment-related harms or exacerbation of ME symptoms.

This article details the lived experience of one family in which both siblings have ME and comorbidities.

6   Recommendations based on our experiences

Because ME impacts every moment of the lives of people with ME, rehabilitation specialists (physical therapists, occupational therapists, etc.) must do the following in order to help people with ME:

  • understand PEM, hypersensitivities, reduced cognitive and physical resources, unrefreshing sleep, and pervasive exhaustion

  • streamline therapy for people with ME

  • reduce frequency/appointment duration/intensity of treatment but also expect treatment to take much longer than usual

  • be mindful that if the person with ME does not have a caregiver to help convey things, progress may be even slower due to the dual effort of communication and therapy

  • anticipate periods of time during which people with ME cannot attend appointments because of physical and cognitive limitations

  • ensure people with ME are not penalized for missed appointments

  • know that because of limited cognitive and physical resources it may be necessary to repeat exercises/activities and rephrase instructions to ensure they are accurately learned

  • keep in mind that each person with ME has different limits and these may also vary from one moment/hour/day to the next

  • know that when it comes to exertion, the person with ME must be the one to determine each time if exertion is in any way feasible

  • understand that assessment and treatment of comorbidities in people with ME requires flexibility on the part of rehabilitation specialists.

Conclusion

To ensure the greatest chance of successful treatment of comorbidities in people with ME, rehabilitation specialists must be cognizant of the impact of ME on cognitive and physical function and must individualize treatment modalities in order to accommodate persons with ME. Careful adaptation of treatment modalities will increase the possibility of successful treatment of comorbidities in people with ME.

 

Posted in News | Tagged , , , , | Comments Off on Impact of ME on treatment of comorbidities: a lived experience

A proposal for explaining progression from light/moderate to severe chronic fatigue

A proposal for explaining progression from light/moderate to severe chronic fatigue, by Anna Dorothea Höck in ES Journal of Nutritional Health vol 1, no.2 Jun 11 2020

 

Research abstract:

Background:

Chronic mild to moderate fatigue is also called chronic idiopathic fatigue. Physicians at best consider psychotherapy for treatment. But most physicians do not view this condition as a real disease.

In contrast, debilitating chronic severe disease has been termed chronic fatigue syndrome (CFS), or if more severe, myalgic encephalopathy (CFS/ME). Meanwhile published metabolic aberrations in CFS/ME suggest estimating these diseases no longer as mere psychiatric diseases. The metabolic results inspire to further exploration of cell stress response mechanisms, which are summarized in this paper.

Interestingly, cell stress responses were tightly linked to vitamin D3 – mediated effects, such as homeostatic regulation of metabolism, energy and redox balance, as well as defense against pathogens and toxins. Specific personality traits, prevalence of indoor activities, latitude and climate predispose to vitamin D3 deficiency, which is supposed to represent a missing link for a comprehensive model of disease progression from mild chronic fatigue to most severe forms.

By diagnosing vitamin D deficiency in early stages of chronic fatigue, the progression to severe and debilitating chronic fatigue may be prevented. In more severe stages of chronic fatigue, such as CFS/ME, resistance against mere vitamin D replenishment seems to be the rule. Some causal mechanisms for this resistance and potential treatment options are shown.

Conclusion:

Scientific insight to the biomolecular mechanisms of cell homeostasis helps to understand and treat all clinically manifestations associated with different stages of chronic fatigue.

 

Excerpt from conclusion:

Physicians could be stimulated to revise their treatment regimens by omitting all interventions which induce further redox stress and xenobiotic burden. The drug
and chemical intolerances of CFS/ME patients call for only minor dosages of pain and psychoactive substances. Instead, restoration of effective VDR activity should be
targeted. This is assumed to stabilize a SIRT1/Nrf2-driven stress response.

This might be achieved by plant based diets and/or supplementations, such as those recommended by Naviaux et al. [8], and Xiao W 2018 [31], 8/10 including all B vitamins, and by supplements of vitamin D3 and minerals, which include calcium and magnesium,
in particular. Phosphate deficiency through long-standing vitamin D deficiency should be considered as well.

Due to presumed vitamin D3 resistance and to distinct genomic and translational vitamin D3 responses, personalized high doses such as 250 mcg cholecalciferol and up to 2400 mg calcium per day should be applied [57,58]. Careful clinical observations should clarify the potential reversibility of very severe and long-standing CFS/ME stages. In any case, any sort of stressful challenge, such as xenobiotics, drugs, nutrient additions, microwaves, and psychosocial stress, should be avoided as much as possible.

Posted in News | Tagged , , , , , , | Comments Off on A proposal for explaining progression from light/moderate to severe chronic fatigue

What ME/CFS caregivers want you to know

What ME/CFS caregivers want you to know, by Bobbie Ausubel in Work vol. 66, no. 2, pp. 361-364, 2020 July 20 [DOI: 10.3233/WOR-203171]

 

Eight stories comprise this paper:

Stories were written in 2019 from caregivers, parents, and spouses, most of whom live with a pwME (person with ME). To protect those in our care, some authors have not used their full names.

Each patient suffers from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a neuro-immune disease which affects each person differently, with a great variety of symptoms and a wide spectrum of disease burden. The National Academy of Medicine says ME/CFS is three times more common in women than men (1), and they estimate that 80% of patients have not yet received a diagnosis (2).

Through their experiences caring for loved ones with ME/CFS, these caregivers have anecdotes and requests for future doctors and occupational therapists to assist with servicing their suffering pwMEs.

  • J., Mother and at-home caregiver of a pwME
  • Courtney Miller, at-home caregiver and wife of Robert Miller, an ME/CFS patient of 30 years
  • Elizabeth B. Burlingame, mother and at-home caregiver of a pwME
  • Katy C., mother of a pwME
  • Bev., mother of a pwME
  • Martin W., father of a pwME
  • B., mother of a pwME
  • MLiz C., friend of two pwME

Read the stories

Posted in News | Tagged , , | Comments Off on What ME/CFS caregivers want you to know

Graded Exercise Therapy doesn’t restore the ability to work in ME/CFS. Rethinking of a Cochrane Review

Graded Exercise Therapy doesn’t restore the ability to work in ME/CFS. Rethinking of a Cochrane review, by Mark Vink, Friso Vink-Niese in Work vol. 66, no. 2, pp. 283-308, 20 July 2020 [doi:10.3233/WOR-203174]

 

Research abstract:

Background:

Cochrane recently amended its exercise review for myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) in response to an official complaint.

Objective:

To determine if the amended review has addressed the concerns raised about the previous review and if exercise is an effective treatment that restores the ability to work in ME/CFS.

Method:

The authors reviewed the amended Cochrane exercise review and the eight trials in it by paying particular interest to the objective outcomes. We also summarised the recently published review of work rehabilitation and medical retirement for ME/CFS.

Results:

The Cochrane review concluded that graded exercise therapy (GET) improves fatigue at the end of treatment compared to no-treatment. However, the review did not consider the unreliability of subjective outcomes in non-blinded trials, the objective outcomes which showed that GET is not effective, or the serious flaws of the studies included in the review. These flaws included badly matched control groups, relying on an unreliable fatigue instrument as primary outcome, outcome switching, p-hacking, ignoring evidence of harms, etc. The review did also not take into account that GET does not restore the ability to work.

Conclusion:

GET not only fails to objectively improve function significantly or to restore the ability to work, but it’s also detrimental to the health of≥50% of patients, according to a multitude of patient surveys. Consequently, it should not be recommended.

 

Excerpts from paper:

5. Conclusion

The recently amended Cochrane exercise review for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) concluded that graded exercise therapy (GET) improves fatigue at the end of treatment compared to no-treatment. Larun et al. also concluded that there is no evidence that GET is safe. However, the review continues to ignore the unreliability of subjective outcomes in non-blinded studies and fails to address other key flaws of the studies in the review. These flaws included:

1) using criteria that also select people who do not have the disease;
2) not excluding patients with a psychiatric or self-limiting illness;
3) badly matched control groups;
4) relying on an unreliable fatigue instrument as primary outcome;
5) not using objective outcomes and/or ignoring them;
6) outcome switching;
7) p-hacking;
8) ignoring evidence of multi-system biological pathologies that can not be explained by their psychological treatment rationale;
9) ignoring evidence of harms.

Analysis of the objective outcomes shows that GET does not lead to clinically significant objective improvement. It also does not lead to improvement of CFS symptoms count or quality of life measurements, which remains lower for those with ME/CFS, than in many other debilitating illnesses.

Only 5% of patients recover. Many patients are unable to work and those who can work, often need a reduction in hours and/or reduction of physical intensity. Unfortunately, GET doesn’t restore the ability to work. Instead, more patients are unable to work and more are reliant on illness benefits after being treated with GET than before treatment with it.

Finally, to use the words of three leading exercise physiologists in the field of ME/CFS, “graded exercise [therapy]…not only fails to improve function, but is detrimental to the health of [ME/CFS] patients and should not be recommended” [106]

 

3.6 Important factors enabling a return to work

According to a report by NIVEL, the Netherlands Institute for Health Services Research [92], there are a number of important things which enabled ME/CFS patients to (return to) work. For 92%, the most important thing was support in finding the right balance between work and spare time. The second most important thing (84%), was support and cooperation from the employer to enable patients to continue to work. Other important things were the following:

• supplying information about ME/CFS to colleagues and superiors (62%);
• changing tasks (61%);
• reducing the number of hours they had to work (61%);
• more rest periods during working times (60%);
• the availability of a special rest place at work (45%);
• working from home (52%);
• individual support and coaching in general (51%);
• and by an occupational health physician in particular (44%);
• adjustments to working conditions (furniture, physical aids) (38%);
• and a regulation or provision for commuting to work (36%).

Posted in News | Tagged , , , , , , , , , | Comments Off on Graded Exercise Therapy doesn’t restore the ability to work in ME/CFS. Rethinking of a Cochrane Review

Properties of measurements obtained during Cardiopulmonary Exercise Testing in individuals with ME/CFS

Properties of measurements obtained during Cardiopulmonary Exercise Testing in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by Todd E Davenport, Staci R Stevens, M A Jared Stevens, Christopher R Snell, J Mark VanNess in Work vol. 66, no. 2, pp. 247-256, 2020 Jul 20 [doi: 10.3233/WOR-203170]

 

Research abstract:

Background:

Diminished cardiopulmonary exercise test (CPET) performance indicates the physiological basis for reduced capacity for activities of daily living and work. Thus, it may be a biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Objective:

To determine statistical properties of cardiac, pulmonary, and metabolic measurements obtained during CPET in people with ME/CFS.

Methods:

Fifty-one females with ME/CFS and 10 sedentary females with similar age and body mass received cardiac, pulmonary, and metabolic measurements during 2 CPETs separated by 24 hours. Two-way analysis of variance and effect size calculations (Cohen’s d) were used to assess the magnitude and statistical significance of differences in measurements between groups. Reliability of CPET measurements was estimated using intraclass correlation coefficients (formula 2,1; ICC2,1). Responsiveness of CPET measurements was assessed using minimum detectable change outside the 95% confidence interval (MDC95) and coefficients of variation (CoV).

Results:

CPET measurements demonstrated moderate to high reliability for individuals with ME/CFS. Comparing subjects with ME/CFS and control subjects yielded moderate to large effect sizes on all CPET measurements. MDC95 for all individuals with ME/CFS generally exceeded control subjects and CoVs for CPET measurements were comparable between groups.

Conclusions:

CPET measurements demonstrate adequate responsiveness and reproducibility for research and clinical applications.

Posted in News | Tagged , , , , , , , | Comments Off on Properties of measurements obtained during Cardiopulmonary Exercise Testing in individuals with ME/CFS

Video: Hospital Admissions: issues and alternatives for severely ill ME/CFS patients

Dialogues ME-CFS video: Hospital Admissions: issues and alternatives for
severely ill ME/CFS patients.

 

A new 16 minute video has been published in the Severe ME series on the Dialogues ME-CFS website

 

Contributers include: Dr Nigel Speight, Dr  Luis Nacul, Naomi Whittingham, Emily Collingridge’s mother & Welsh parent Rob.

There are lots of practical suggestions for health & social care professionals, paramedics & advocates.

 

 

Posted in News | Tagged , , , , , | Comments Off on Video: Hospital Admissions: issues and alternatives for severely ill ME/CFS patients

Post-exertional symptoms distinguish ME/CFS subjects from healthy controls

Post-exertional symptoms distinguish Myalgic Encephalomyelitis/Chronic Fatigue Syndrome subjects from healthy controls, by  in Work, vol. 66, no. 2, pp. 265-275, 20 Jul 2020 [doi: 10.3233/WOR-203168]

 

Research abstract:

Background:

Post-exertional malaise (PEM) is an exacerbation of symptoms that leads to a reduction in functionality. Recognition of PEM is important for the diagnosis and treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Objective:

Symptoms following cardiopulmonary exercise testing were compared between ME/CFS patients and healthy controls.

Methods:

Open-ended questionnaires were provided to subjects following two maximal exercise tests, 24 hours apart. Subjects evaluated how they felt at five time points. Responses were classified into 19 symptom categories.

Results:

ME/CFS subjects (n = 49) reported an average of 14±7 symptoms compared to 4±3 by controls (n = 10). During the seven days afterwards, ME/CFS subjects reported 4±3 symptoms. None were reported by controls. Fatigue, cognitive dysfunction, and sleep problems were reported with the greatest frequency. ME/CFS patients reported more symptom categories at higher frequencies than controls. The largest differences were observed in cognitive dysfunction, decrease in function, and positive feelings.

Conclusions:

A standardized exertional stimulus produced prolonged, diverse symptoms in ME/CFS subjects. This provides clues to the underlying pathophysiology of ME/CFS, leading to improved diagnosis and treatment.

 

5. Conclusion

The presence of symptoms during and after the two-day CPET and the extended recovery time in the ME/CFS group exemplify PEM. Two key symptoms, cognitive dysfunction and a decrease in function, can potentially indicate the occurrence of PEM. This is consistent with a 2019 survey of 1,534 ME/CFS subjects where the top selected PEM consequence was “reduced stamina and functional ability” (selected by 99.4%) followed by “physical fatigue” (98.9%), “cognitive exhaustion” (97.4%), and “problems thinking” (97.4%). Other complaints prominent in ME/CFS patients after activity are fatigue, muscle/joint pain, headaches and sleep disturbances. The disparity in the time to recover may serve as an additional marker. These symptoms and the rate of recovery contribute to the existing literature on PEM and assist health care professionals in recognizing PEM.

By discerning both the attributes of PEM and its manifestations in each patient, health care providers can identify patients with ME/CFS and devise patient-specific treatment plans to combat the onset and reduce the severity of symptoms. OTs are already familiar with the concepts of energy conservation and activity management but these concepts may need to be modified for ME/CFS patients. For example, more rest may be needed following activity compared to other medical conditions. Patients may reach a plateau of activity which is improved but not close to “normal” since the physiological underpinnings of ME/CFS are not yet fully understood. Early diagnosis and symptom management promote the maintenance of or even improvement in patient function.

This paper also sheds light on the possible risks of a 2-day CPET. It does not appear that patients or research subjects suffer permanent or protracted damage from CPET. Our data show that recovery is bimodal, with approximately half of subjects taking a week or less to recover. This information can be shared with patients or research subjects so that they might make a better informed decision. Exploration of this bimodal pattern may also help discover subgroups within or the pathophysiology underlying ME/CFS.

Posted in News | Tagged , , , , , , , , , , | Comments Off on Post-exertional symptoms distinguish ME/CFS subjects from healthy controls

Managing CFS through exercise with clinician and researcher Dr Nancy Klimas

Blog post and podcast: How To Exercise If You Have Chronic Fatigue: Managing chronic fatigue syndrome with clinician and researcher Dr Nancy Klimas, by Dr. Michael Ruscio, July 14, 2020

 

Dr Nancy Klimas talks to Dr Michael Ruscio about ME & exercise.

Key Takeaways

  • Chronic Fatigue Syndrome patients should do very short exercise sessions (1-3 minutes), raising their heart rate no more than 30 beats per minute above their normal baseline.
  • Patients should rest to return heart rate to baseline between these short sessions.
  • Address oxidative stress, inflammation, and cell function to treat ME/CFS.
  • “You can’t rest your way out of this illness.”

 

In This Episode

About Dr. Nancy Klimas … 00:05:08
What is CFS? … 00:06:07
Is CFS a Post-Viral Illness? … 00:07:26
CFS Prevalence … 00:09:51
CFS Predispositions … 00:10:38
How to Exercise With CFS … 00:12:23
CFS Treatment Approach … 00:20:46
CFS Medications and Treatment … 00:24:58
Natural Anti-Virals … 00:28:40
New CFS Research … 00:30:57

 

 

Exercise Tips for Chronic Fatigue Syndrome

Physical activity can be very difficult for people with Chronic Fatigue Syndrome. Even a small walk to the bathroom or the mailbox can leave them completely exhausted and bedridden, let alone 30 minutes of exercise.

Dr. Klimas explained that chronic fatigue patients have an extremely low aerobic threshold, and understanding this is key to creating an exercise regime that doesn’t leave them with a chronic fatigue flare up. “They’re much better doing short, but frequent exercise than to try to go longer on endurance.”

Key Exercise Tips:

  • Do short bouts of exercise with adequate rest in between to allow the heart rate to return to your baseline.
  • Keep heart rate within 30 beats per minute of your resting heart rate.
  • Let the patient be the guide.
  • Keep a log to track progress and understand flares.

She said, “You have to find this gentle way of moving them along and doing little short bits that they can tolerate. And then they’ll become more and more confident when they don’t crash, that they can do a little more…”

Listen to / or download the podcast and read more about ME/CFS from Dr Nancy Klimas

Posted in News | Tagged , , , | Comments Off on Managing CFS through exercise with clinician and researcher Dr Nancy Klimas